Topical superoxide dismutase reduces post‐irradiation breast cancer fibrosis
暂无分享,去创建一个
A Fourquet | G. Tsakiris | A. Fourquet | E. Gez | F. Campana | S. Zervoudis | F Campana | S Zervoudis | B Perdereau | E Gez | C Badiu | G Tsakiris | S Koulaloglou | C. Badiu | B. Perdereau | S. Koulaloglou
[1] W. Huber. Orgotein--(bovine Cu-Zn superoxide dismutase), an anti-inflammatory protein drug: discovery, toxicology and pharmacology. , 1981, European journal of rheumatology and inflammation.
[2] O. S. Nielsen,et al. Orgotein in radiation treatment of bladder cancer. A report on allergic reactions and lack of radioprotective effect. , 1987, Acta oncologica.
[3] Anna Niwin¯ska,et al. Cosmetic evaluation of breast conserving treatment for mammary cancer , 1998 .
[4] S. Batra,et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer , 2004, Breast Cancer Research and Treatment.
[5] O. S. Nielsen,et al. Lack of radiation protective effect of orgotein in normal and malignant mammalian cells. , 1979, Acta radiologica: oncology, radiation, physics, biology.
[6] E. E. Vogin,et al. Safety tests of orgotein, an antiinflammatory protein. , 1973, Toxicology and applied pharmacology.
[7] H. Cramer,et al. Radioprotective effect of free radical scavenging enzymes. , 1990, The Journal of otolaryngology.
[8] I. Turesson. Individual variation and dose dependency in the progression rate of skin telangiectasia. , 1990, International journal of radiation oncology, biology, physics.
[9] John A. Tainer,et al. Structure and mechanism of copper, zinc superoxide dismutase , 1983, Nature.
[10] N. Robert,et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Martin,et al. Abnormal phenotype of cultured fibroblasts in human skin with chronic radiotherapy damage. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[12] M. Monte,et al. [Free radicals of oxygen and superoxide dismutase. Biological and medical aspects]. , 1994, Medicina.
[13] G. Lorette,et al. Lésions cutanées induites par la radiothérapie: prévention, traitements , 2001 .
[14] R. Mehvar. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[15] A. Hart,et al. Dose and volume effects on fibrosis after breast conservation therapy. , 1994, International journal of radiation oncology, biology, physics.
[16] E van der Schueren,et al. Cosmetic evaluation of breast conserving treatment for mammary cancer. 2. A quantitative analysis of the influence of radiation dose, fractionation schedules and surgical treatment techniques on cosmetic results. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] H. Duan,et al. MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. , 2003, Antioxidants & redox signaling.
[18] H. Iwase,et al. [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[19] A. Brahme,et al. Principles and Practice of Radiation Oncology , 1992 .
[20] I. Andrulis,et al. Genetic Variants of GPX1 and SOD2 and Breast Cancer Risk at the Ontario Site of the Breast Cancer Family Registry , 2004, Cancer Epidemiology Biomarkers & Prevention.
[21] A. Petkau,et al. Radioprotection by superoxide dismutase of macrophage progenitor cells from mouse bone marrow. , 1984, Biochemical and biophysical research communications.
[22] I. Fridovich,et al. A direct demonstration of the catalytic action of superoxide dismutase through the use of pulse radiolysis. , 1972, The Journal of biological chemistry.
[23] P. Schlienger,et al. Conservative management of operable breast cancer. Ten years experience at the Foundation Curie , 1978, Cancer.
[24] L. Machet,et al. [Radiation-induced skin toxicities: prevention, treatment]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[25] H. Magdelenat,et al. Effects of superoxide dismutase topical treatment on human skin radiofibrosis: a pathological study , 1996 .
[26] J. McCord,et al. Free Radicals as Mediators of Tissue Injury , 1980 .
[27] F. Baillet,et al. [Action of liposomal superoxide dismutase on measurable radiation-induced fibrosis]. , 1989, Annales de medecine interne.
[28] S Hellman,et al. The effect of adjuvant chemotherapy on the cosmetic results after primary radiation treatment for early stage breast cancer. , 1984, International journal of radiation oncology, biology, physics.
[29] S. Kharb,et al. Serum biochemical markers in carcinoma breast. , 2003, Indian journal of medical sciences.
[30] F. Baillet,et al. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[31] A. Petkau. Scientific basis for the clinical use of superoxide dismutase. , 1986, Cancer treatment reviews.
[32] I. Fentiman,et al. Assessment of skin dose and its relation to cosmesis in the conservative treatment of early breast cancer. , 1988, International journal of radiation oncology, biology, physics.
[33] F. Holmes,et al. Consequences of breast irradiation in patients with pre-existing collagen vascular diseases. , 1989, International journal of radiation oncology, biology, physics.
[34] I. Turesson,et al. The influence of fraction size in radiotherapy on the late normal tissue reaction--I: Comparison of the effects of daily and once-a-week fractionation on human skin. , 1984, International journal of radiation oncology, biology, physics.